论文部分内容阅读
[目的]评价多西他赛同期放化疗治疗老年非小细胞肺癌的近期疗效和毒副反应。[方法]2006年3月至2008年8月156例老年性非小细胞肺癌患者随机分为单纯化疗组56例,单纯放疗组52例,同期放化疗组48例。[结果]同期放化疗组近期疗效总有效率(CR+PR)为79.2%,显著高于单纯放疗组的50.0%(P<0.05)。同期放化疗组的1年生存率(72.7%)高于单纯放疗组的44.0%(P<0.05)。同期放化疗组的急性放射毒副作用较单纯放疗组多见,但均以轻度反应(Ⅰ～Ⅱ级)为主,经积极治疗不影响治疗计划。[结论]多西他赛同期放化疗对晚期非小细胞肺癌放疗有增敏作用,近期疗效满意,且毒副反应较轻,可以耐受。
[Objective] To evaluate the short-term curative effect and toxicity of docetaxel for concurrent chemotherapy and radiotherapy for senile non-small cell lung cancer. [Method] From March 2006 to August 2008, 156 patients with senile non-small cell lung cancer were randomly divided into chemotherapy group (56 cases), radiotherapy alone group (52 cases) and radiotherapy and chemotherapy group (48 cases). [Results] The total effective rate (CR + PR) of the concurrent chemoradiotherapy group was 79.2%, significantly higher than that of the radiotherapy alone group (50.0%, P <0.05). The 1-year survival rate (72.7%) in radiotherapy and chemotherapy group was higher than that in radiotherapy alone group (44.0%, P <0.05). The side effects of radiotherapy and chemotherapy in the radiotherapy and chemotherapy group were more common than those in the radiotherapy group, but mild reactions (grade Ⅰ ~ Ⅱ) were the main symptoms. The active treatment did not affect the treatment plan. [Conclusions] Docetaxel radiotherapy and chemotherapy have sensitization to radiotherapy of advanced non-small cell lung cancer in the same period. The recent curative effect is satisfactory, and the side effects are mild and tolerable.